Waters CORP /DE/

Waters Corporation announced robust second quarter 2026 financial results, exceeding guidance with strong revenue growth and raising its full-year financial outlook.

Waters Corporation announced first quarter 2026 financial results, exceeding revenue guidance and raising full-year forecasts following the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses.

Augusta SpinCo Corporation, a Waters Corporation subsidiary, successfully completed a $3.5 billion senior notes offering to refinance existing debt.

Waters Corporation finalized its acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business, creating a combined entity with significant debt and lower pro forma earnings.

Waters Corporation finalized its Reverse Morris Trust transaction with Becton, Dickinson and Company, integrating BD's Biosciences & Diagnostic Solutions businesses and forming a global life sciences and diagnostics leader.

Waters Corporation announced robust fourth quarter and full-year 2025 financial results, highlighted by double-digit non-GAAP EPS growth and the strategic acquisition of BD Biosciences and Diagnostic Solutions.

Waters Corporation reported a net loss for the first quarter of 2026, significantly impacted by the recent acquisition of Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business.

Waters Corporation reported an 8% increase in Q3 net sales to $799.9 million, driven by strong demand for Waters Division products, though operating income declined due to significant merger-related and ERP implementation costs.

Waters Corporation reported a 9% increase in Q2 2025 net sales and a 3% rise in net income, while announcing a transformative $17.5 billion merger with BD's Biosciences & Diagnostic Solutions business.

Waters Corporation's Q1 2025 sales increased by 4%, driven by strong demand for LC, MS, and LC & MS instrument systems.

Waters Corporation's Q3 2024 results show a 4% increase in net sales, driven by strong customer demand, but year-to-date sales are down 2% due to delayed capital spending.

Waters Corporation's second-quarter results show a decrease in sales and operating income, impacted by lower customer demand and acquisition-related expenses, despite growth in recurring revenues.

Waters Corporation announced a 7% increase in net sales for 2025, alongside the transformative $16.8 billion acquisition of BD's Biosciences and Diagnostic Solutions businesses, significantly expanding its market presence.

Waters Corporation's 2024 revenue remained flat year-over-year, primarily due to a significant decline in sales from China, despite growth in other geographic regions.

Waters Corporation's 2023 10-K filing reveals a year of mixed results, marked by a decline in sales in China, strategic acquisitions, and ongoing investments in research and development.

Waters Corporation Director Heather Knight acquired 63.03 common stock units on June 30, 2026, as a non-cash director fee compensation.

Waters Corporation Director Wei Jiang has reported the acquisition of 3,572.75 shares of common stock, received in lieu of director fees.

Robert L. Carpio III, SVP at Waters Corp, sold 189 shares of common stock to cover tax obligations related to vested restricted stock units.

Waters Corp SVP & CFO Amol Chaubal reported a transaction involving the withholding of common stock for tax obligations and the acquisition of shares through an employee stock purchase plan.

Jianqing Bennett, SVP at Waters Corp, reported a transaction involving the withholding of shares for tax obligations.

Director Wei Jiang acquired common stock units in Waters Corp, valued at $64.06 each, as a substitute for director fees.

Waters Corporation's 2026 proxy statement details strong 2025 financial performance, the acquisition of BD's Biosciences & Diagnostic Solutions, and governance updates.

Waters Corporation will hold its annual shareholder meeting virtually on May 22, 2025, to vote on director elections, auditor ratification, executive compensation, and an employee stock purchase plan.

Waters Corporation is entering a new era of growth, focusing on operational excellence, new product launches, and expanding into adjacent markets, while maintaining strong corporate governance and shareholder returns.

Waters Corporation will hold its annual shareholder meeting on May 23, 2024, to elect directors, ratify the selection of PricewaterhouseCoopers LLP, approve executive compensation, and amend the company's certificate of incorporation.

Waters Corporation's proxy statement outlines proposals for shareholder voting, including officer exculpation and executive compensation, while reviewing the company's performance and governance.

Fundsmith LLP has reported beneficial ownership of 4,308,930 shares, representing 4.4% of the outstanding Common Stock of Waters Corp.

Vanguard Capital Management has reported a beneficial ownership of 7.49% in Waters Corp's common stock as of March 31, 2026.

The Vanguard Group has reported zero beneficial ownership in Waters Corp common stock following an internal realignment that disaggregated reporting responsibilities.

AllianceBernstein L.P. has increased its beneficial ownership in Waters Corp to 3.5% of common stock, holding 2,084,443 shares for investment purposes.

The Vanguard Group has reported an increased beneficial ownership of 12.86% in Waters Corp common stock, totaling 7,656,891 shares.

AllianceBernstein L.P. has reported a 6.8% beneficial ownership stake in Waters Corp common stock, held for investment purposes.